Distinct and Overlapping Pathways Contribute to the Efficacy of Nivolumab-Based Regimens in Patients with Gastro-Oesophageal Adenocarcinoma By Ogkologos - March 26, 2025 1017 0 Facebook Twitter Google+ Pinterest WhatsApp Biomarker analyses from the CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Greater Severity of Adverse Events in Women Across Multiple Anticancer Treatment... February 11, 2022 Two Years of Adjuvant Palbociclib Added to Endocrine Therapy Does Not... December 9, 2021 FDA Approves Sodium Thiosulfate to Reduce the Risk of Ototoxicity Associated... October 13, 2022 Prognostic Value of Longitudinal ctDNA Assessment in Oesophageal Cancer January 11, 2021 Load more HOT NEWS Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients... FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma Androgen Receptor Pathway Inhibitors Outperform Taxanes in Patients with mCRPC with... Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian
